Hypersensitivity Reactions Associated with Platinum Antineoplastic Agents: a Systematic Review

Overview

Journal Met Based Drugs

Specialty Chemistry

Date 2010 Oct 2

PMID 20886011

Citations 68

Authors

Nektaria Makrilia

Ekaterini Syrigou

Ioannis Kaklamanos

Leonidas Manolopoulos

Muhammad Wasif Saif

Affiliations

Soon will be listed here.

Abstract

Platinum-containing chemotherapy agents (cisplatin, carboplatin, oxaliplatin) have been approved in the first-line setting of numerous malignancies, such as ovarian, bladder, head and neck, colorectal, and lung cancer. Their extensive use over the last decade has led to a significant increase in the incidence of hypersensitivity reactions, which are defined as unforeseen reactions whose signs and symptoms cannot be explained by the known toxicity of these drugs. Skin rash, flushing, abdominal cramping, itchy palms, and back pain are common symptoms. Cardiovascular and respiratory complications can prove fatal. Multiple pathogenetic mechanisms have been suggested. Hypersensitivity usually appears after multiple infusions, suggesting type I allergic reactions; however, other types of hypersensitivity also seem to be implicated. Several management options are available to treating physicians: discontinuation of chemotherapy, premedication, prolonging of infusion duration, desensitization protocols, and replacement with a different platinum compound after performing skin tests that rule out cross-reactions among platinum agents.

Citing Articles

Rapid Desensitization to Antitumoral Agents. Result from a Retrospective Study, DESARCh.

Tessari R, Ossato A, Realdon F, Montresor V, Giovagnoni G, Giannini M Hosp Pharm. 2024; 00185787241278702.

PMID: 39558941 PMC: 11569765. DOI: 10.1177/00185787241278702.

Delayed and immediate cutaneous adverse events during pembrolizumab combination chemotherapy against cervical cancer: Case series.

Adachi T, Matsui T, Okata-Karigane U, Takahashi C, Tahara U, Hyodo M J Dermatol. 2024; 52(1):132-137.

PMID: 39526614 PMC: 11700920. DOI: 10.1111/1346-8138.17521.

Basophil activation test is a complementary tool in the diagnosis of immediate reactions to platinum salts and taxanes.

Bogas G, Ariza A, Vazquez-Revuelta P, Labella M, Madrigal-Burgaleta R, Fernandez-Santamaria R Allergy. 2024; 80(1):271-286.

PMID: 39215539 PMC: 11724245. DOI: 10.1111/all.16296.

Hypersensitivity reaction to injection hyaluronidase after multiple eye surgery: Presentation, management, and preventive strategies.

Venkatakrishnan J Indian J Ophthalmol. 2024; 72(8):1216-1218.

PMID: 39078969 PMC: 11451797. DOI: 10.4103/IJO.IJO_3309_23.

A survey of carboplatin desensitization therapy in Japan: A multicenter retrospective study.

Komatsu H, Matsumoto K, Morita M, Nagasawa T, Nishio H, Suzuki J Cancer Med. 2024; 13(5):e6968.

PMID: 38491829 PMC: 10943373. DOI: 10.1002/cam4.6968.

References

Markman M, Hsieh F, Zanotti K, Webster K, Peterson G, Kulp B . Initial experience with a novel desensitization strategy for carboplatin-associated hypersensitivity reactions: carboplatin-hypersensitivity reactions. J Cancer Res Clin Oncol. 2003; 130(1):25-8. DOI: 10.1007/s00432-003-0501-3. View

Polyzos A, Tsavaris N, Kosmas C, Arnaouti T, Kalahanis N, Tsigris C . Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience. Oncology. 2001; 61(2):129-33. DOI: 10.1159/000055363. View

Jones R, Ryan M, Friedlander M . Carboplatin hypersensitivity reactions: re-treatment with cisplatin desensitisation. Gynecol Oncol. 2003; 89(1):112-5. DOI: 10.1016/s0090-8258(03)00066-0. View

Charpidou A, Tsagouli S, Tsimpoukis S, Vassias A, Makrilia N, Stratakos G . Triplet combination of carboplatin, irinotecan, and etoposide in the first-line treatment of extensive small-cell lung cancer: a single-institution phase II study. Anticancer Drugs. 2010; 21(6):651-5. DOI: 10.1097/CAD.0b013e3283393718. View

Georgoulias V, Ardavanis A, Tsiafaki X, Agelidou A, Mixalopoulou P, Anagnostopoulou O . Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol. 2005; 23(13):2937-45. DOI: 10.1200/JCO.2005.04.016. View

Bautista M, Stevens W, Chen C, Curtis B, Aster R, Hsueh C . Hypersensitivity reaction and acute immune-mediated thrombocytopenia from oxaliplatin: two case reports and a review of the literature. J Hematol Oncol. 2010; 3:12. PMC: 2859393. DOI: 10.1186/1756-8722-3-12. View

Callahan M, LaChance J, Stone R, Kelsey J, Rice L, Jazaeri A . Use of cisplatin without desensitization after carboplatin hypersensitivity reaction in epithelial ovarian and primary peritoneal cancer. Am J Obstet Gynecol. 2007; 197(2):199.e1-4. DOI: 10.1016/j.ajog.2007.04.044. View

Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J . Continued chemosensitivity to cisplatin/carboplatin in ovarian carcinoma despite treatment with multiple prior platinum-based regimens. Gynecol Oncol. 1997; 65(3):434-6. DOI: 10.1006/gyno.1997.4708. View

Zweizig S, Roman L, Muderspach L . Death from anaphylaxis to cisplatin: a case report. Gynecol Oncol. 1994; 53(1):121-2. DOI: 10.1006/gyno.1994.1098. View

10.

Shepherd G . Hypersensitivity reactions to chemotherapeutic drugs. Clin Rev Allergy Immunol. 2003; 24(3):253-62. DOI: 10.1385/CRIAI:24:3:253. View

11.

Brandi G, Pantaleo M, Galli C, Falcone A, Antonuzzo A, Mordenti P . Hypersensitivity reactions related to oxaliplatin (OHP). Br J Cancer. 2003; 89(3):477-81. PMC: 2394366. DOI: 10.1038/sj.bjc.6601155. View

12.

Robinson J, Singh D, Wharton J, Gershenson D, Wolf J . Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies. Gynecol Oncol. 2001; 82(3):550-8. DOI: 10.1006/gyno.2001.6331. View

13.

Gowda A, Goel R, Berdzik J, Leichman C, Javle M . Hypersensitivity Reactions to oxaliplatin: incidence and management. Oncology (Williston Park). 2005; 18(13):1671-5. View

14.

Leguy-Seguin V, Jolimoy G, Coudert B, Pernot C, Dalac S, Vabres P . Diagnostic and predictive value of skin testing in platinum salt hypersensitivity. J Allergy Clin Immunol. 2007; 119(3):726-30. DOI: 10.1016/j.jaci.2006.11.640. View

15.

Medioni J, Coulon M, Morere J, Hennebelle F, Piperno-Neumann S, Breau J . Anaphylaxis after oxaliplatin. Ann Oncol. 1999; 10(5):610. DOI: 10.1023/a:1026498513593. View

16.

Koren C, Yerushalmi R, Katz A, Malik H, Sulkes A, Fenig E . Hypersensitivity reaction to cisplatin during chemoradiation therapy for gynecologic malignancy. Am J Clin Oncol. 2002; 25(6):625-6. DOI: 10.1097/00000421-200212000-00020. View

17.

Shlebak A, Clark P, Green J . Hypersensitivity and cross-reactivity to cisplatin and analogues. Cancer Chemother Pharmacol. 1995; 35(4):349-51. DOI: 10.1007/BF00689458. View

18.

Polyzos A, Syrigos K, Stergiou J, Panopoulos C, Potamianou A, Vamvakas L . Phase I trial of weekly docetaxel with a 4-weekly cisplatin administration in patients with advanced gastric carcinoma. Cancer Chemother Pharmacol. 2005; 55(5):466-70. DOI: 10.1007/s00280-004-0912-0. View

19.

Wrzesinski S, McGurk M, Donovan C, Ferencz T, Saif M . Successful desensitization to oxaliplatin with incorporation of calcium gluconate and magnesium sulfate. Anticancer Drugs. 2007; 18(6):721-4. DOI: 10.1097/CAD.0b013e32802ffbcb. View

20.

Herrero T, Tornero P, Infante S, Fuentes V, Sanchez M, de Barrio M . Diagnosis and management of hypersensitivity reactions caused by oxaliplatin. J Investig Allergol Clin Immunol. 2006; 16(5):327-30. View